Funding to start a business

Startup funding for new businesses

Starting out is the hardest time to find funding, because most programs want to see a track record. The programs below are the ones that fund new and early businesses, including research awards and training programs.

Check each listing for what stage of business it expects. If a program asks for something you do not have yet, note it and come back once you do.

56 open listings in this group

Showing the 24 closing soonest. Use the search page to see the rest.

Job announcement
Therapeutic Medical Physicist
Veterans Health Administration
Basic Requirements: United States Citizenship: Non-citizens may only be appointed when it is not possible to recruit qualified citizens in accordance with VA Policy. English Language Proficiency Requirement - Per VA Handbook 5005, Part II, Chapter 3, Section A, Paragraph 3j: No person will be appointed under authority of 38 U.S.C., chapter 73 or 74, to serve in a direct patient-care capacity in VHA who is not proficient in written and spoken English. Education. Master's degree or higher in a physics, science, or engineering discipline recognized by an accredited college or university with at least 30 semester hours in medical physics, health physics, radiological science, physics, engineering, chemistry, or biology; or an equivalent foreign degree and coursework substantiated by the National Association of Credential Evaluation Services. Board Certification. Persons hired or reassigned to TMP positions in the VHA must be board certified in the field of therapeutic medical physics by an approved certifying body. The board certificate must be current and the applicant must abide by the certifying body's requirements for continuing education. Approved Certifying Bodies The American Board of Radiology (ABR) in any of the following field titles: Therapeutic Medical Physics Therapeutic Radiologic or Therapeutic Radiological Physics Radiologic Physics or Radiological Physics The American Board of Medical Physics (ABMP) in the subfield of Radiation Oncology Physics. The Canadian College of Physicists in Medicine (CCPM) in the subfield of Radiation Oncology Physics. Exception for Non-Board Certified, Entry Level Candidates. Non-board certified TMPs designated by the certifying agency (e.g., American Board of Radiology) as "board eligible", who otherwise meet the eligibility requirements, may be given a temporary appointment as a graduate TMP under the authority of 38 U.S.C. § 7405(c)(2)(B). The appointing official may waive the requirement of certification for a period not to exceed 2 years for a TMP that provides care under the supervision of a board certified TMP at or above the full performance level. This exception only applies at the GS-12 entry level. For grade levels at or above the full performance level, the candidate must be board certified. Temporary appointments of non-board certified TMPs may not be extended beyond 2 years, or converted to a new temporary appointment. May qualify based on being covered by the Grandfathering Provision as described in the VA Qualification Standard for this occupation (only applicable to current VHA employees who are in this occupation and meet the criteria). Grade Determinations: GS-12 Therapeutic Medical Physicist (Entry Level): Experience. None beyond the basic requirements. AND Demonstrated Knowledge, Skills, and Abilities. In addition to the experience above, the candidate must demonstrate the following KSAs: Knowledge of the scientific and technical principles and properties of radiotherapy devices for external beam radiotherapy. This includes specialized knowledge of the clinical applications of these devices. Ability to exercise independent judgment in the calibration and commissioning of external beam photon and electron beam delivery devices for clinical use. This includes specialized knowledge of the acceptance testing and commissioning of radiation therapy treatment simulation equipment such as Computerized Tomography (CT) simulators. Scientific and technical knowledge of electronic data handling techniques and software.4.Ability to exercise independent judgment in the safe operation of radiotherapy equipment and quality assurance. This includes specialized knowledge of sources of uncertainty associated with treatment delivery and how to minimize the deviation between planned and delivered treatments; configuration of test equipment and associated software; and expected equipment performance for external beam radiotherapy treatment, brachytherapy, and simulation equipment. Detailed scientific and technical knowledge of radiotherapy treatment planning principles, treatment planning algorithms, and treatment delivery. Knowledge of scientific and technical aspects of brachytherapy delivery systems and radiation sources. Ability to exercise independent judgment in radiation shielding techniques for external beam delivery systems. This includes specialized knowledge of detection and survey methods for external beam delivery systems. This also includes knowledge of regulatory requirements and guidelines for radiation shielding and protection. Knowledge of multi-modality medical imaging to include a detailed scientific and technical understanding of megavoltage photon beam imaging, CT, radiographic imaging, magnetic resonance imaging, and positron emission computed tomography. GS-13 Therapeutic Medical Physicist (Full Performance Level): In addition to the basic requirements, qualified candidates must possess the experience and demonstrate the KSA requirement described below. Experience. In addition to the basic requirements, qualified candidates must have completed of a minimum of 1-year of progressively complex experience equivalent to the next lower grade level. That experience must be reflected in the candidate's resume and demonstrate possession and use of the GS-12 (Entry Level) KSAs above. AND Demonstrated Knowledge, Skills, and Abilities. In addition to the experience above, the candidate must demonstrate the following KSAs: Knowledge regarding the safe and efficient use of all radiotherapy devices for external beam radiotherapy. The ability to evaluate and ensure correct and safe operation of radiotherapy equipment through complex problem diagnosis and scheduled quality assurance. Knowledge of the scientific, clinical, and technical applications of high dose rate and low dose rate brachytherapy treatment simulation, planning, dosimetry, and treatment methods. Expertise in the professional, scientific, and technical aspects of shielding methods for external beam radiation delivery systems, radiation survey methods, developing procedures, setting action levels, delivering radiation safety training, developing and documenting competencies, and reporting. This includes an in-depth knowledge of regulatory requirements and guidelines for radiation shielding and personnel protection. Ability to exercise independent professional judgment in the performance and evaluation of calibration, acceptance testing, and clinical commissioning procedures for all types of external beam photon and electron beam delivery systems. Skilled in the evaluation of acceptance testing and commissioning results of CT simulators. Technical skills in 3-D treatment planning, intensity modulated radiation therapy treatment planning, and stereotactic body radiation therapy planning. This includes specialized knowledge of clinical process steps and resource requirements for planning and delivery of radiation oncology treatments. Ability to process information from multi-modality imaging datasets for treatment planning, treatment verification, and radiotherapy response assessment. Preferred Experience: Experience with Elekta linear accelerators Experience with Raystation treatment planning system and/or Mim software Experience within the VA Reference: For more information on this qualification standard, please visit https://www.va.gov/ohrm/QualificationStandards/. The full performance level of this vacancy is GS-13. The actual grade at which an applicant may be selected for this vacancy is in the range of GS-12 to GS-13. Physical Requirements (CONTINUED IN EDUCATION SECTION)
Location:
San Antonio, Texas
Pay:
$177,304 to $228,000
Closes:
Sep 30, 2026
Funding opportunityGrant
Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed)
National Institutes of Health
This notice of funding opportunity (NOFO) seeks to establish a course to equip researchers studying drug use, drug misuse, and drug addiction with the skills, knowledge, and practical tools needed to translate their scientific discoveries into impactful real world solutions. The course is envisioned to focus on building capacity in product development, entrepreneurship, and innovation pathways so participants can more effectively move biomedical ideas from early research toward implementation, or commercialization. By combining structured training, mentorship, and hands-on experience, the course is envisioned to accelerate the development of biomedical products that address the complex challenges of drug use, drug misuse, and drug addiction, while fostering an interdisciplinary community of investigators prepared to navigate the scientific, regulatory, and business aspects of this unique research field.
Closes:
Oct 1, 2026
Funding opportunityGrant
Engineering Research Initiation (ERI)
U.S. National Science Foundation
The NSF Directorate for Engineering (ENG) seeks to build engineering research capacity across the nation by investing in new academic investigators who have yet to receive sufficient research funding from Federal Agencies. The Engineering Research Initiation (ERI) program will support new investigators as they initiate their research programs and advance in their careers as researchers, educators, and innovators. This funding opportunity aims to broaden the base of investigators involved in engineering research and therefore is limited to investigators that are not affiliated with “very high research activity” R1 institutions (according to the Carnegie Classification https://carnegieclassifications.iu.edu/ ).
Amount:
$200,000
Closes:
Oct 9, 2026
Funding opportunityGrant
NSF Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs: A Pilot Emphasis on Scientific Instrumentation
U.S. National Science Foundation
NSF invests in scientific discoveries, technological breakthroughs, and transformative innovations that strengthen economic growth, enhance security, and improve the lives of Americans and people around the world. Our ability to support that mission requires a robust scientific and engineering (S&E) enterprise in the United States that allows scientists to innovate at the frontier. In addition to funding scientists, America needs next-generation scientific instrumentation that allows scientists to pursue new innovations. In many fields, it is critical that this new scientific instrumentation is developed in the United States. In support of this mission, NSF is initiating a pilot emphasis area for its SBIR/STTR programs to invest in startups and small businesses that are specifically developing enabling technologies that include next-generation instrumentation, novel experimental platforms, and other scientific equipment to advance the frontiers of scientific discovery and strengthen the American scientific and engineering enterprise. This encompasses novel instrumentation necessary for the coming era of AI-driven discoveries. This pilot will prioritize investing in the necessary infrastructure to support entirely new fields of scientific discovery, making new technological breakthroughs and transformative applications possible. Through this approach, NSF will continue to lead in propelling the scientific enterprise to new frontiers. This pilot emphasis area for the NSF SBIR/STTR programs funds across enabling technology areas and market sectors in alignment with the above goals; the programs do not solicit specific technologies for the purpose of procuring goods and services for the agency from startups and small businesses. NSF will continue to invest in other deep-tech ventures through the historic NSF SBIR/STTR programs available here. Funding opportunities are available through the NSF SBIR/STTR programs: Phase I, Phase II, Fast-Track, and Supplements. Each company can receive up to $2.0 million for R&D. Separately, NSF welcomes Strategic Breakthrough proposals, upon recommendation from the Program Officer, for Phase II awardees. NSF takes no equity and awardees keep full ownership of their company and intellectual property. Expanding Participation in STEM and Gold Standard Science: NSF prioritizes cutting-edge discovery science and engineering research, advancing technology and innovation, and creating opportunities for all Americans. NSF also expects the highest standards of scientific rigor, integrity and adherence to tenets of Gold Standard Science in proposals, as appropriate for the field of science and research modality.
Closes:
Nov 4, 2026
Funding opportunityGrant
Plasma Physics
U.S. National Science Foundation
Proposals in the area of plasma physics submitted to the Division of Physics that are not governed by another solicitation (such as CAREER), should be submitted to the Division-wide solicitation: Division of Physics: Investigator-Initiated Research Projects . The Plasma Physics program participates in multiple NSF meta-programs such as the ECosytem for Leading Innovation in Plasma Science and Engineering (ECLIPSE) , Windows on the Universe: The Era of Multi-Messenger Astrophysics (WoU-MMA) , and Computational and Data-enabled Science and Engineering (CDS&E) . Topically appropriate proposals may also be submitted to the Plasma Physics program in response to NSF Dear Colleague Letters such as Critical Aspects of Sustainability (CAS): Innovative Solutions to Sustainable Chemistry (CAS-SC) . When permitted under an MOU between NSF and another funding agency or private foundation, NSF may share information from proposals submitted to this solicitation for consideration of joint funding, and may invite employees of such organizations to attend merit review panels as observers. MOUs of relevance to the Plasma Physics program presently exist with the Department of Energy/Office of Science, National Nuclear Security Administration, the Air Force Office of Scientific Research, the US-Israel Binational Science Foundation, the Czech Science Foundation, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), and the Swiss National Science Foundation. Plasma Physics is a study of matter and physical systems whose intrinsic properties are governed by collective interactions of large ensembles of free charged particles. 99.9% of the visible Universe is thought to consist of plasmas. The underlying physics of the collective behavior in plasmas has applications to space physics and astrophysics, materials science, applied mathematics, fusion science, accelerator science, and many branches of engineering. The Plasma Physics program supports research that can be categorized by several broad, sometimes overlapping, sub-areas of the discipline, including: magnetized plasmas in the laboratory, space, and astrophysical environments; high energy density plasmas; low temperature plasmas; dusty, ultra-cold, and otherwise strongly coupled plasmas; non-neutral plasmas; and intense field-matter interaction in plasmas. The focus of the Plasma Physics program is to generate an understanding of the fundamental principles governing the physical behavior of a plasma via collective interactions of large ensembles of free charged particles, as well as to improve the basic understanding of the plasma state as needed for other areas of science and engineering. Principal Investigators (PIs) are encouraged to consider including specific efforts to increase diversity of the plasma physics community and broaden participation of under-represented groups in Science, Technology, Engineering, and Mathematics (STEM) as Broader Impacts of proposed work. Development of new undergraduate and graduate plasma physics curricula, or curricula enhancement to include plasma physics topics in other courses, at institutions lacking such coursework is similarly encouraged. NSF recognizes that some research projects within this Program may require more than three years to realize demonstrable research outcomes. For such projects, PIs are encouraged to consult the above Program Director to discuss the possibility of submitting a proposal of 4- or 5-year duration. Some Plasma Physics-related activities are supported primarily by other NSF Programs. Proposals focused on the physical properties of individual or a small number of atoms or molecules, or optical physics, should be directed to the Atomic, Molecular, and Optical Physics Program within the Division of Physics. Proposals focused on understanding astrophysical systems should be directed to the Division of Astronomical Sciences. Proposals focused on understanding the Geospace environment or the Sun-Earth interactions should be directed to an appropriate program within the Geospace Section of the Division of Atmospheric and Geospace Sciences. Proposals focused on development of new materials using plasmas should be directed to an appropriate program in the Division of Materials Research. Proposals focused on plasma-assisted manufacturing should be directed to the Division of Civil, Mechanical and Manufacturing Innovation. Finally, proposals focused on use of plasmas for environmental and reaction engineering, environmental sustainability, combustion systems, or engineering of biomedical systems should be directed to an appropriate program within the Division of Chemical, Bioengineering, Environmental and Transport systems.
Closes:
Nov 16, 2026
Funding opportunityGrant
National Science Foundation Translation to Practice
U.S. National Science Foundation
The U.S. NSF Directorate for Technology, Innovation and Partnerships (NSF TIP) partners across sectors to advance three primary focus areas – accelerating technology translation and development, fostering regional innovation and economic growth, and preparing the American workforce for future high-wage jobs in STEM fields. The translation of research to practice ensures that the insights and innovations developed through scientific study and experimentation have tangible, positive impacts for the Nation. These impacts include improving the quality of life, promoting economic and job growth, ensuring national security, and maintaining global competitiveness. Indeed, scientific and engineering breakthroughs have the potential to address critical societal challenges in industries such as aerospace, agriculture, communications, education, energy, healthcare, national security, and transportation – but the translation of discoveries and innovations from the laboratory to society often takes many forms including non-linear pathways. The NSF TTP program was developed with several goals in mind: To identify and support use-inspired research and translational activities enabling a continuum from foundational research to practice; To develop partnerships and collaborations between institutions of higher education and other entities (e.g., industry, state/local/national government agencies, philanthropies, open-source ecosystems, for-benefit, for-profit and non-profit organizations, international organizations, etc.); To promote and advance the education and training of students and postdoctoral researchers, encouraging the participation of all Americans in STEM including innovation and entrepreneurship; and To identify future customer needs and opportunities and bring these to the forefront in the conduct of use-inspired research and translational activities. The NSF TTP program offers three tracks that represent different starting points or stages in moving discoveries and innovations from the laboratory to practice: NSF TTP-Explore (NSF TTP-E) is a pilot track that is likely to be the first step for researchers seeking to translate their basic research to practice. To be eligible for the NSF TTP-E track, proposers must have an active, eligible, NSF research award (see Eligibility Information for further details). TTP-E is designed to encourage current, eligible NSF awardees to intentionally pursue applications of their research with the potential for societal impact. The NSF TTP-E track provides the opportunity to obtain an extension of the initial award period of a current NSF award for up to two years in order to offer investigators an opportunity to explore adventurous, high-risk, use-inspired research and initial translational activities as the starting point for translation that was not covered by the original research award. NSF TTP-Translate (NSF TTP-T) starts with use-inspired research and initial translational activities and further matures the idea(s), iterates and improves the solution(s), and lowers the barrier(s) to effective translation of research from lab to practice. NSF TTP-Partner (NSF TTP-P) supports translational efforts that demand one or more partnerships for technology development and deployment. Here, strategic partnerships with stakeholders beyond U.S. institutions of higher education are essential ingredients for success and may include industry partners, government entities at all levels, philanthropies, international organizations, or other groups associated with large scale productization and distribution. The NSF TTP-P track requires an NSF-Catalyzed Partnership with an organization that will assist in the translation to practice. In addition to the Principal Investigator (PI), NSF TTP-P proposals must include a co-PI or Senior/Key Personnel who is a member or employee of the NSF-Catalyzed Partner. Partnerships with U.S. institutions of higher education are valued, but NSF TTP strongly prioritizes NSF-Catalyzed Partnerships that are able to help bring the product, process, or service to the market, potentially through licensing agreements, startup or small business formation, incorporation into an existing open-source ecosystem, development into standards setting arrangements, etc.
Amount:
$600,000 to $2,000,000
Closes:
Nov 17, 2026
Funding opportunityGrant
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
National Institutes of Health
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Closes:
Jan 7, 2027
Job announcement
Therapeutic Medical Physicist- Recruitment Incentive Authorized
Veterans Health Administration
Basic Requirements: United States Citizenship: Non-citizens may only be appointed when it is not possible to recruit qualified citizens in accordance with VA Policy. English Language Proficiency. TMPs must be proficient in spoken and written English as required by 38 U.S.C. 7402(d), and 7407(d). Education. Master's degree or higher in a physics, science, or engineering discipline recognized by an accredited college or university with at least 30 semester hours in medical physics, health physics, radiological science, physics, engineering, chemistry, or biology; or an equivalent foreign degree and coursework substantiated by the National Association of Credential Evaluation Services. Board Certification. Persons hired or reassigned to TMP positions in the VHA must be board certified in the field of therapeutic medical physics by an approved certifying body. The board certificate must be current and the applicant must abide by the certifying body's requirements for continuing education. Approved Certifying Bodies(a) The American Board of Radiology (ABR) in any of the following field titles: 1. Therapeutic Medical Physics 2. Therapeutic Radiologic or Therapeutic Radiological Physics 3. Radiologic Physics or Radiological Physics (b) The American Board of Medical Physics (ABMP) in the subfield of Radiation Oncology Physics.(c) The Canadian College of Physicists in Medicine (CCPM) in the subfield of Radiation Oncology Physics. May qualify based on being covered by the Grandfathering Provision as described in the VA Qualification Standard for this occupation (only applicable to current VHA employees who are in this occupation and meet the criteria). Exception for Non-Board Certified, Entry Level Candidates. Non-board certified TMPs designated by the certifying agency (e.g., American Board of Radiology) as "board eligible", who otherwise meet the eligibility requirements, may be given a temporary appointment as a graduate TMP under the authority of 38 U.S.C. § 7405(c)(2)(B). The appointing official may waive the requirement of certification for a period not to exceed 2 years for a TMP that provides care under the supervision of a board certified TMP at or above the full performance level. This exception only applies at the GS-12 entry level. For grade levels at or above the full performance level, the candidate must be board certified. Temporary appointments of non-board certified TMPs may not be extended beyond 2 years, or converted to a new temporary appointment. May qualify based on being covered by the Grandfathering Provision as described in the VA Qualification Standard for this occupation (only applicable to current VHA employees who are in this occupation and meet the criteria). GS-13 Therapeutic Medical Physicist (Full Performance Level) Experience. In addition to the basic requirements, completion of a minimum of 1 year of progressively complex experience equivalent to the next lower grade level. Assignments. The full performance level TMP is board certified and performs the clinical practice of therapeutic medical physics in its entirety with considerable discretion and independent judgment. The employee plans, delivers, verifies, and monitors quality assurance of radiotherapy at all levels of complexity. Specific tasks include: recommending an optimal modality and treatment technique for the patient; evaluating the quality, safety, and accuracy of radiation treatments planned and delivered to patients, thus ensuring that radiation dose is carried out correctly and completely; and safely operating all radiation planning and delivery devices. Demonstrated Knowledge, Skills, and Abilities. In addition to the experience above, the candidate must demonstrate the following KSAs: 1. Knowledge regarding the safe and efficient use of all radiotherapy devices for external beam radiotherapy. 2. The ability to evaluate and ensure correct and safe operation of radiotherapy equipment through complex problem diagnosis and scheduled quality assurance. 3. Knowledge of the scientific, clinical, and technical applications of high dose rate and low dose rate brachytherapy treatment simulation, planning, dosimetry, and treatment methods. 4. Expertise in the professional, scientific, and technical aspects of shielding methods for external beam radiation delivery systems, radiation survey methods, developing procedures, setting action levels, delivering radiation safety training, developing and documenting competencies, and reporting. This includes an in-depth knowledge of regulatory requirements and guidelines for radiation shielding and personnel protection. 5. Ability to exercise independent professional judgment in the performance and evaluation of calibration, acceptance testing, and clinical commissioning procedures for all types of external beam photon and electron beam delivery systems. Skilled in the evaluation of acceptance testing and commissioning results of CT simulators. 6. Technical skills in 3-D treatment planning, intensity modulated radiation therapy treatment planning, and stereotactic body radiation therapy planning. This includes specialized knowledge of clinical process steps and resource requirements for planning and delivery of radiation oncology treatments. 7. Ability to process information from multi-modality imaging datasets for treatment planning, treatment verification, and radiotherapy response assessment. Preferred Experience: The ideal candidate for the position of Therapeutic Medical Physicist should possess a minimum of 5 years of experience in the field of therapeutic medical physics. They should hold a current certification by the American Board of Radiology (ABR) or the American Board of Medical Physics (ABMP) in Therapeutic Radiologic Physics or an equivalent certification. This individual should have substantial experience in advanced radiation therapy techniques, including but not limited to, intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Proficiency in the use of treatment planning systems, linear accelerators, and associated quality assurance equipment and protocols is essential. Additionally, the candidate should demonstrate active involvement in clinical research, publication in peer-reviewed journals, and participation in professional organizations. Effective communication skills, collaborative abilities, and a commitment to maintaining the highest standards of patient care and safety are also critical for this role. Reference: For more information on this qualification standard, please visit https://www.va.gov/ohrm/QualificationStandards/. The full performance level of this vacancy is GS-13. Physical Requirements: The work is sedentary. Some work may require movement between offices, hospitals, warehouses, and similar areas for meetings and to conduct work. Work may also require walking/standing, in conjunctions with travel to and attendance at meetings and/or conferences away from the work site. Incumbent may carry and lift light items weighing less than 15 pounds.
Location:
Dallas, Texas
Pay:
$149,008 to $193,713
Closes:
Mar 11, 2027
Job announcement
Supervisory Therapeutic Medical Physicist - RELOCATION/RECRUITMENT INCENTIVE
Veterans Health Administration
Basic Requirements: Citizenship. Citizen of the United States. (Non-citizens may be appointed when it is not possible to recruit qualified citizens in accordance with chapter 3, section A, paragraph 3g, this part.) Education. Master's degree or higher in a physics, science, or engineering discipline recognized by an accredited college or university with at least 30 semester hours in medical physics, health physics, radiological science, physics, engineering, chemistry, or biology; or an equivalent foreign degree and coursework substantiated by the National Association of Credential Evaluation Services. Board Certification. Persons hired or reassigned to TMP positions in the VHA must be board certified in the field of therapeutic medical physics by an approved certifying body. The board certificate must be current and the applicant must abide by the certifying body's requirements for continuing education. Approved Certifying Bodies (a) The American Board of Radiology (ABR) in any of the following field titles: 1. Therapeutic Medical Physics 2. Therapeutic Radiologic or Therapeutic Radiological Physics 3. Radiologic Physics or Radiological Physics (b) The American Board of Medical Physics (ABMP) in the subfield of Radiation Oncology Physics. (c) The Canadian College of Physicists in Medicine (CCPM) in the subfield of Radiation Oncology Physics. Grade Determinations: GS-14 Supervisory Therapeutic Medical Physicist Experience: In addition to the basic requirements, you must have completion of a minimum of 1 year of progressively complex experience equivalent to the next lower grade and must demonstrate the following knowledge, skills, and abilities to perform at this grade level: 1. Ability to oversee the technical development and implementation of new radiotherapy techniques and modalities. This includes knowledge of current standards of care, VA policies, trends and changes in delivery technology, as well as fair, principled, and decisive leadership practices. 2. Ability to optimize technical infrastructure and workflow for streamlined operations in the department of radiation oncology. This includes the knowledge and application of techniques such as Failure Mode and Effect Analysis (FMEA), Root Cause Analysis (RCA), and Fault Tree Analysis (FTA). 3. Ability to assess the qualifications and abilities of current and prospective employees, to include staff performance evaluations and professional development. 4. Advanced knowledge of regulatory requirements, manufacturer's standards, and professional society guidelines for performing quality assurance of radiation therapy equipment to include accelerators, simulators, and high dose rate/low dose rate brachytherapy delivery systems. 5. Ability to use written and verbal communication with a strong command of technical writing considerations. 6. Ability to collaborate with the members of other disciplines and supervisors and to represent the profession both in and outside of VHA. This includes knowledge of the roles, contributions, and interrelationships with other health care specialties and supporting divisions. 7. Knowledge of instructional methods and documenting competencies.8. Ability to manage and supervises employees. Assignments: For all assignments above the full performance level, the higher-level duties must consist of significant scope, complexity (difficulty), and range of variety, and be performed by the incumbent at least 25% of the time. A supervisory TMP provides professional, scientific, and clinical practice of therapeutic medical physics for external beam and brachytherapy treatment procedures from treatment simulation to treatment planning to the actual treatment delivery. The incumbent oversees the technical development and 8 implementation of new radiotherapy techniques and modalities; oversees the activities of all other TMPs, dosimetrists, and other staff members assigned to the unit; directs the technical aspects of treatment procedures; and, performs duties qualifying them as a supervisor to include planning and directing work, developing performance plans, evaluating staff performance, and other administrative functions. The supervisory TMP has full supervisory responsibility for a staff that includes lower level TMP positions and other clinical and professional staff within the unit. The employee directs the implementation of new equipment and processes through oversight of the following activities: assesses radiation therapy equipment needs; monitors acceptance testing and commissioning of new radiation therapy equipment; evaluates the adequacy of room shielding and radiation surveys; develops and implements treatment processes in concert with a radiation oncologist; and, ensures the precision and accuracy of treatment delivery. The employee optimizes technical infrastructure and workflow for streamlined operations in the department of radiation oncology through the mastery and application of techniques such as Failure Mode and Effect Analysis (FMEA), Root Cause Analysis (RCA), and Fault Tree Analysis (FTA). The employee directs the radiation therapy treatment planning team through oversight of the following activities: designs and approves of treatment plans; monitors the accuracy of treatment data recorded in the patient's medical records; provides consultation to the radiation oncologist regarding difficult treatment cases; performs patient-specific treatment validation measurements; develops medical physics policies and procedures for the delivery and quality assessment of advanced treatment modalities such as intensity modulated radiation therapy, stereotactic body radiation therapy and brachytherapy. The employee develops, operates, and documents the medical physics quality assurance program; ensures regulatory compliance; supervises the Radiation Safety Officer's radiation safety program; and, trains and educates radiation oncology team members in safe operations in Radiation Oncology. Preferred Experience: Should possess a minimum of 10 years of experience in the field of therapeutic medical physics, with at least 5 years in a leadership or supervisory role. This individual should have extensive experience in advanced radiation therapy techniques, including but not limited to, intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT). Proficiency in the use of treatment planning systems, linear accelerators, and associated quality assurance equipment and protocols is essential. Demonstrate a strong track record of involvement in clinical research, publication in peer-reviewed journals, and participation in professional organizations. Effective communication skills, collaborative abilities, and a proven commitment to maintaining the highest standards of patient care and safety are also critical for this role. Reference: For more information on this qualification standard, please visit https://www.va.gov/ohrm/QualificationStandards/. The actual grade at which an applicant may be selected for this vacancy is in the GS-14
Location:
Dallas, Texas
Pay:
$185,054 to $228,000
Closes:
Mar 11, 2027
Funding opportunityGrant
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
National Institutes of Health
The Small Business Technology Transfer (STTR) grant program helps United States small business concerns (SBCs) that partner with a nonprofit research institution bring scientific innovations to the marketplace. The STTR program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.
Closes:
Apr 5, 2027
Funding opportunityGrant
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
National Institutes of Health
The Small Business Innovation Research (SBIR) program helps United States small business concerns (SBCs) bring scientific innovations to the marketplace. The SBIR program supports feasibility studies to later research and development (R&D) needed to develop a commercial product.
Closes:
Apr 5, 2027
Funding opportunityGrant
LPS Qubit Collaboratory (LQC)
Dept of the Army -- Materiel Command
The U.S. Army Research Office (ARO) in partnership with NSA’s Laboratory for Physical Science (LPS) is soliciting Incubator, Collaboration, and Fellowship research proposals for participation in the LPS Qubit Collaboratory (LQC). The mission of the LQC can be captured in three broad goals: 1) pursue disruptive fundamental research and enabling technologies with a focus on qubit development for quantum computing and other applications (such as sensing); 2) grow deep, collaborative partnerships to tackle the most difficult and relevant long-term problems in quantum information science and technology; and 3) build a quantum workforce of tomorrow through research experiences in government at LPS and at LQC partners. The LQC will offer a mechanism for collaborative research between LPS and academia, industry, FFRDCs, and Government Laboratories to advance foundational and transformative research on challenging problems that have hindered progress in quantum information processing and associated technologies. The goal of this BAA is to seek proposals that bring together expertise from the public and private sectors and their respective research infrastructures to advance solutions that may be best approached as a collaborative team. A Collaboratory is “a center without walls, in which the nation’s researchers can perform their research without regard to physical location, interacting with colleagues, accessing instrumentation, sharing data and computational resources, [and] accessing information in digital libraries. This BAA introduces LQC Research Thrusts ( A.1.1 ) which are the technical areas of interest—which will be updated periodically—where partners of the LQC will pursue joint research with LPS through Incubator ( A.1.2 ) and Collaboration ( A.1.3 ) collaborative agreements. The LQC BAA also fulfills the Government’s overarching interest--through the proposed research and on-site research experiences--in creating and training a workforce in quantum science and technology, generating pathways of solutions that feed technology development, establishing partnerships, and creating transition opportunities. In further support of training through research, Section A.1.4 calls for Quantum Computing Research (QuaCR) Graduate and Postdoctoral Fellowships for US citizens working in areas of interest. Substantial progress on solving the most difficult and long-term Quantum Information Science & Technology (QIST) research problems that unleash further rapid progress in the field will constitute LQC success. Examples of such research problems include (but are not limited to): limits of performance due to device design, material selection, and/or control, the exploration of alternative qubit physics (e.g., different approaches to qubit encoding or types of gates) and lowering of barriers to such approaches, advances in materials that improve qubit gate fidelity, reducing the overhead of classical components in quantum information technology and optimizing classical performance, and the exploration of applications of quantum technologies to new domains. Three categories of proposals are sought for this BAA: 1.Incubator opportunities seek partnership proposals from single investigators and small research groups, including teaching colleges, who may have unique skillsets to contribute toward the pursuit of the research thrusts presented in A.1.1. Incubator proposals may also be the development of concepts into a detailed technical research approach to advance solution of problems of high interest to quantum information science research. Incubator proposals would avail themselves of the collaboration opportunities with LPS research staff and infrastructure made available at the Laboratory for Physical Sciences (LPS) to lay the groundwork for concepts that may be suitable for a Collaboratory proposal or responses to other DoD quantum information science research opportunities. 2.Collaboratory proposals seek research proposals that bring together a strong significant collaboration--researchers from academia, industry, FFRDCs, and/or Government Laboratories--to pursue long-term projects focused on fundamental problems of interest to qubit development and/or associated science and technology. These collaborative groups will propose to work together in a focused manner for a period of time expected to be one to three years in order to demonstrate a proof-of-concept experiment and/or theory exploration to determine the feasibility of their creative idea. 3.QuaCR Research Fellowship proposals seek to support talented U.S. citizen graduate students and postdoctoral researchers in the field of quantum information processing (primary interest) and quantum sensing (secondary interest). Applicants with a background from either within or outside QIS are encouraged. The proposed research areas are described in this BAA and must enhance active Quantum Information Science research efforts being supported by the Army Research Office and/or LPS. Research fellows are encouraged to complete an LPS Internship during their graduate career or visit during their postdoctoral fellowship. Funding Opportunity Title: LPS Qubit Collaboratory Special Research Topics Announcement: W911NF21S0009-SPECIALNOTICE-1 The U.S. Army Combat Capabilities Development Command (DEVCOM), Army Research Laboratory (ARL)-Army Research Office (ARO) is looking for proposed research and development solutions under the Broad Agency Announcement (BAA) W911NF21S0009-2 for Basic and Applied Scientific Research in Quantum Computing. The title for this Special Notice is “LPS Qubit Collaboratory Special Topics.” Upon receipt, compliant proposals will be reviewed through a technical and programmatic process in accordance with the evaluation criteria referenced in the W911NF21S0009-2 LQC BAA to determine which proposal may be awarded Grant, Cooperative Agreement, or Procurement Contract under this topic.
Closes:
Apr 30, 2027
Funding opportunityGrant
Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)
National Institutes of Health
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this notice of funding opportunity (NOFO) seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners. Specific research interests of participating NIH ICOs are detailed within.
Closes:
May 7, 2027
Funding opportunityGrant
EPSCoR Research Infrastructure Improvement Program: EPSCoR Research Incubators for STEM Excellence (E-RISE)
U.S. National Science Foundation
The Established Program to Stimulate Competitive Research (EPSCoR) supports the mission of the U.S. National Science Foundation (NSF) by promoting nationwide scientific progress. Through this program, NSF fosters partnerships among academic institutions, government entities, industry, and non-profits. These collaborations aim to drive long-term improvements in research infrastructure, enhance R&D capacity, and boost the research competitiveness of eligible EPSCoR jurisdictions, including states, territories, and commonwealths. A jurisdiction’s research ecosystem is the interconnected network of institutions, organizations, researchers, trainees, community stakeholders, and resources that contribute to the process of research and innovation that advances fundamental knowledge, generates use-inspired products, and ultimately cultivates beneficial societal impacts for a jurisdiction. E-RISE supports hypothesis-driven or problem-driven research and fosters the development of research teams and products in a scientific topical area that aligns with a jurisdiction’s research ecosystem and priorities, as detailed in the jurisdiction’s Science and Technology (S&T) Plan or drawn from other jurisdiction plans, reports, or publications prepared by appropriate authorities or bodies. E-RISE invites innovative proposals within the chosen research area that will lead to development and implementation of sustainable broad networks of individuals, institutions, and organizations, and that will transform the science, technology, engineering and mathematics (STEM) research capacity and competitiveness in a jurisdiction. E-RISE is particularly interested in proposals that justify exploring emerging or interdisciplinary research areas with high potential impact. E-RISE projects must have a clearly articulated research goal that will lead to new knowledge by addressing a clear hypothesis or problem. The E-RISE project should promote (i) areas of research capacity-building within a chosen research topic; (ii) development of a skilled workforce that is relevant to the research topic, as well as the project and its outcomes; (iii) a culture of collaboration and engagement across different types of academic institutions and organizations, as well as non-academic sectors (e.g., industry and government); (iv) integration of the research with societal impacts; and (v) a clear sustainability plan to preserve the resulting research incubator's team and products beyond E-RISE funding.
Amount:
$8,000,000
Closes:
Aug 10, 2027
Funding opportunityGrant
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Institutes of Health
The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Closes:
Oct 25, 2027
Funding opportunityGrant
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
National Institutes of Health
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Closes:
Oct 25, 2027
Funding opportunityGrant
Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.
Amount:
$6,250,000
Closes:
Nov 15, 2027
Funding opportunityGrant
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
National Institutes of Health
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational supportneeded for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
Closes:
Dec 23, 2027
Funding opportunityGrant
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
National Institutes of Health
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
Closes:
Dec 23, 2027
Funding opportunityGrant
Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
National Institutes of Health
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. This is a phased initiative for early stage projects. The R61 phase provides support to identify and test initial prototype designs, to identify a disease target and generate experimental design, and to identify, test and pilot research tools. The R33 phase provides support for continued prototype development and testing, in addition to modifying design features and user feedback, diagnostic product generation, exploration of assay components, and characterization of a load design, and research tool improvement, large trial testing and data integration. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
Closes:
Dec 23, 2027
Funding opportunityGrant
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
National Institutes of Health
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.
Amount:
$350,000
Closes:
Dec 23, 2027
Funding opportunityGrant
Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
National Institutes of Health
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
Closes:
Dec 23, 2027
Funding opportunityGrant
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
National Institutes of Health
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Closes:
Jan 7, 2028
Funding opportunityGrant
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
National Institutes of Health
The Commercialization Readiness Pilot (CRP) program helps small business concerns (SBCs) move NIH-funded SBIR or STTR projects from late-stage development to commercialization. The CRP supports later-stage research and development (R&D) and/or technical assistance that Phase II and Phase IIB Strategic Breakthrough awards do not typically support. This includes:Independent replication or confirmation of key studiesIND- or IDE-enabling studiesClinical studiesManufacturing scale-up and related quality activitiesRegulatory and other specialized technical supportSBCs may subcontract (outsource) a significant amount of the work in a CRP to meet the project goals.
Closes:
Apr 5, 2029

Search all opportunities

Related groups

Ready to apply?

A free account lets you save listings, follow deadlines, and use the application tools.

Create a free account How we check listings